|
US2019284297A1
|
|
Anti-cd3 epsilon antibodies and methods of use thereof
|
|
CA3070519A1
|
|
Generating multispecific antibody mixtures and methods of uses thereof
|
|
CN111201031A
|
|
anti-CD 47x anti-mesothelin antibodies and methods of use thereof
|
|
CA3065008A1
|
|
Anti-cd47 x anti-mesothelin antibodies and methods of use thereof
|
|
AU2017353936A1
|
|
Anti-CD19 antibodies and methods of use thereof
|
|
US2018142015A1
|
|
Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications
|
|
KR20190071785A
|
|
Methods, compositions and dosage regimens for the treatment or prevention of interferon gamma related indications
|
|
EP3512878A1
|
|
Bispecific antibody display on phage surface
|
|
WO2017021552A1
|
|
Methods and compositions for identifying patient populations for diagnosis and treatment of tlr4-dependent disorders
|
|
CN107849127A
|
|
For diagnosing and treating CXCL9 and the elevated patient of other biomarker levels illness
|
|
WO2016156537A1
|
|
Method for optimizing the assembly and production of hetero-multimeric protein complexes
|
|
CN107922476A
|
|
The method of purifying bispecific antibody
|
|
AU2014359077A1
|
|
Anti-TLR4 antibodies and methods of use thereof
|
|
US2015110811A1
|
|
Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of TLR4 ligands and other biomarkers
|
|
CA2922979A1
|
|
Readily isolated bispecific binding molecules with native format having mutated constant regions
|
|
CN105121467A
|
|
Anti-CD47 antibodies and methods of use thereof
|
|
CA2869048A1
|
|
Anti-tlr4 antibodies and uses thereof
|
|
CA2867020A1
|
|
Readily isolated bispecific antibodies with native immunoglobulin format
|
|
AU2012351751A1
|
|
Methods of purifying antibodies
|
|
WO2012098238A1
|
|
Combination therapies and methods using anti-cd3 modulating agents and anti-il-6 antagonists
|
